As of 2015, more than 9 percent of the population -- 30.3 million -- had diabetes. Another 84.1 million had prediabetes, the U.S. Centers for Disease Control and Prevention reported Tuesday.
A new study led by University of Pennsylvania researchers has found that the oral microbiome is affected by diabetes, causing a shift to increase its pathogenicity. The research, published in the journal Cell Host & Microbe this week, not only showed that the oral microbiome of mice with diabetes shifted but that the change was associated with increased inflammation and bone loss.
"Up until now, there had been no concrete evidence that diabetes affects the oral microbiome," said Dana Graves, senior author on the new study and vice dean of scholarship and research at Penn's School of Dental Medicine. "But the studies that had been done were not rigorous."
Scientists at the University of Cambridge have developed a new statistical model which estimates kidney function in patients with cancer. This is the most accurate model for estimating kidney function yet developed and should help cancer specialists treat their patients more safely and improve the accuracy of chemotherapy dosing. The model is now available free online.
Kidneys perform a number of vital functions, including filtering waste and toxins out of the blood, producing vitamin D, and regulating blood pressure. The filtration function of the kidneys is measured by the glomerular filtration rate (GFR), the rate at which blood is passed through the glomeruli, the small blood vessel filters in the kidneys.
Magnesium is a mineral the body uses as an electrolyte, meaning it carries electric charges around the body when dissolved in the blood.
Magnesium has a role in bone health, cardiovascular function, and neurotransmission, among other functions. Most magnesium is stored in the bones.
Newswise — DALLAS – July 05, 2017 – Combination therapy with two immunotherapy drugs produces an unprecedented doubling of response rates from 20 percent to 40 percent, a new study shows.
The multicenter trial involving 100 patients showed that the addition of ipilimumab to nivolumab, which is currently FDA-approved for treatment of kidney cancer, leads to responses that can last beyond two years. Half of the patients in the study, which appears in the Journal of Clinical Oncology, had metastases that had grown while they were on previous therapy.
Results from a recent clinical trial indicate that intensive blood pressure lowering reduces chronic kidney disease (CKD) patients' risks of dying prematurely or developing cardiovascular disease. The findings appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
The appropriate target for blood pressure in patients with CKD and hypertension has been unclear. To examine the issue, researchers analyzed information from the Systolic Blood Pressure Intervention Trial (SPRINT), sponsored by the National Institutes of Health. SPRINT, which enrolled individuals aged ?50 years with systolic blood pressure of ?130 mm Hg and at least one additional cardiovascular disease risk factor, compared targeting a systolic blood pressure to <120 mm Hg vs. <140 mm Hg for preventing cardiovascular complications and early death. The benefits of the lower target were apparent almost a year before the study was initially planned to end.
“I KNOW I sound kind of crazy, but I don’t have any doubts,” says Brittany Burton. “It’s a little bit of a sacrifice, but I’m sure it’s the right thing to do.” Burton, a 27-year-old high-school counsellor from Durham, North Carolina, is talking about donating one of her kidneys to someone she met on the internet.